Table 1.
Baseline Characteristics
| Epirubicin=400 mg/m2 (n=27) | Epirubicin <400 mg/m2 (n=94) | |
|---|---|---|
| Age, y | 51.0 (42.0, 59.0) | 48.5 (43.8, 58.0) |
| Body mass index | 24.5 (22.2, 27.2) | 25.9 (22.9, 29.1) |
| Systolic blood pressure, mm Hg | 135.0 (120.0, 140.0) | 128.5 (120.0, 140.0) |
| Diastolic blood pressure, mm Hg | 80.0 (75.0, 85.0) | 80.0 (74.5, 85.0) |
| Heart rate, beats/min | 71.5±10.3 | 70.9±10.0 |
| Hypertension (n) | 1 (7%) | 7 (7.4%) |
| Diabetes mellitus (n) | 0 (0%) | 2 (2.1%) |
| Current smoking (n) | 6 (22.2%) | 19 (20.2%) |
| Serum creatinine, mg/dL | 0.75 (0.69, 0.81) | 0.72 (0.69, 0.81) |
| Hemoglobin, g/dL | 13.2±0.94 | 13.3±0.81 |
| FEC treatment | ||
| FEC 60 mg/m2×4 (n) | 0 | 71 (75.5%) |
| FEC 60 mg/m2×6 (n) | 0 | 23 (24.5%) |
| FEC 100 mg/m2×4 (n) | 27 (100%) | 0 |
| HER2 status | Positive | Negative |
| Assigned to metoprolol and placebo (n) | 6 | 23 |
| Assigned to candesartan and placebo (n) | 7 | 25 |
| Assigned to metoprolol and candesartan (n) | 7 | 23 |
| Assigned to placebo and placebo (n) | 7 | 23 |
Data are expressed as mean±SD, median (interquartile range) or numbers (percent). FEC indicates 5‐fluorouracil, epirubicin, cyclophosphamide; HER, human epidermal growth factor receptor.